Ann: Kazia releases preliminary Cantrixil Phase I data, page-4

"n general, the drug has encountered few dose-limiting toxicities and, as a result, most dosing cohorts have only required enrolment of a single patient, in line with the trial protocol, which has allowed the study to progress with a number of patients towards the lower extent of the forecast range.?

Great for cost saving but not so good in terms of MTD as we still don't know......but that is a good thing as there seems to be little toxicities at all and SD found in the monotherapy.    Still after a year and half thought we would be sitting on our MTD at least.